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Abstract
Beta-amyloid (Ab ) neurotoxicity is important in Alzheimer’s disease (AD) pathogenesis. Ab neurotoxicity causes oxidative
stress, inflammation and mitochondrial damage resulting in neuronal degeneration and death. Oxidative stress,
inflammation and mitochondrial failure are also pathophysiological mechanisms of type 2 diabetes (T2DM) which is
characterized by insulin resistance. Interestingly, T2DM increases risk to develop AD which is associated with reduced
neuronal insulin sensitivity (central insulin resistance). We studied the potential protective effect of adiponectin (an
adipokine with insulin-sensitizing, anti-inflammatory and anti-oxidant properties) against Ab neurotoxicity in human
neuroblastoma cells (SH-SY5Y) transfected with the Swedish amyloid precursor protein (Sw-APP) mutant, which
overproduced Ab with abnormal intracellular Ab accumulation. Cytotoxicity was measured by assay for lactate
dehydrogenase (LDH) released upon cell death and lysis. Our results revealed that Sw-APP transfected SH-SY5Y cells
expressed both adiponectin receptor 1 and 2, and had increased AMP-activated protein kinase (AMPK) activation and
enhanced nuclear factor-kappa B (NF-kB) activation compared to control empty-vector transfected SH-SY5Y cells.
Importantly, adiponectin at physiological concentration of 10 mg/ml protected Sw-APP transfected SH-SY5Y cells against
cytotoxicity under oxidative stress induced by hydrogen peroxide. This neuroprotective action of adiponectin against Ab
neurotoxicity-induced cytotoxicity under oxidative stress involved 1) AMPK activation mediated via the endosomal adaptor
protein APPL1 (adaptor protein with phosphotyrosine binding, pleckstrin homology domains and leucine zipper motif) and
possibly 2) suppression of NF-kB activation. This raises the possibility of novel therapies for AD such as adiponectin receptor
agonists.
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Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
in the elderly with significant morbidity and mortality [1]. The
exact pathogenetic mechanisms underlyng AD are uncertain. One
extensively studied mechanism is neurotoxicity mediated by beta-
amyloid (Ab) [2–5]. Histopathological studies of brain from AD
patient reveal extracellular accumulation of senile plaques
containing Ab fibrils, intracellular accumulation of neurofibrillary
tangles containing hyperphosphorylated tau, neuronal loss, amy-
loid angiopathy, and inflammation [1,5–6]. Ab peptides, pre-
dominantly Ab40 and Ab42, are derived from cleavage of amyloid
precursor protein (APP), by b secretase and c secretase [2]. Ab
exist in different forms including monomers (peptides), oligomers,
protofibrils and fibrils [7]. The pathogenetic role of Ab in AD is
strongly supported by the observation that familial AD patients
have mutations affecting proteins involved in Ab production or
processing such as APP, presenilin1 and presenilin 2. An example
is the Swedish APP mutation (Sw-APP, APPK670N, M671L ) that
causes familial early-onset AD [8]. Ab is neurotoxic [2–4]. Recent
evidences suggest that Ab oligomers are directly toxic to neurons
and play important roles in early AD [9–12]. Ab oligomers inhibit
long-term potentiation in hippocampal neurons [12], impair
neuronal synaptic transmission by causing loss of excitatory
synapses and dendritic spines [13–14], and may induce un-
controlled ion flux by forming Ca2+-permeable pores in the lipid
membrane [15–16].
Type 2 diabetes mellitus (T2DM) is, similar to AD, common in
the elderly with significant morbidity and mortality. Interestingly,
several pathophysiological features of T2DM are also found in AD.
These include 1) insulin resistance, 2) inflammation, 3) oxidative
stress, and 4) aberrant lipid metabolism [17]. In AD, there are 1)
central insulin resistance resulting from reduction of insulin
receptors and desensitization of insulin receptors in neurons [18–
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21], 2) Ab induced microglial and astrocytic activation and release
of inflammatory mediators which lead to neuroinflammation [22–
24], 3) inhibition of enzymes for mitochondrial oxidative
phosphorylation by Ab leads to increased production of reactive
oxygen species (ROS) which cause oxidative stress [25–26], and 4)
the risk of apolipoprotein E (ApoE) e4 allele. The Rotterdam study
reported that T2DM doubled the risk of dementia and patients on
insulin had 4 times the risk, suggesting that T2DM increases the
risk to develop AD [27]. Consistently, T2DM patients have
elevated serum levels of pro-inflammatory cytokines including IL-
1, IL-6 and TNFa and display increased risk of cognitive decline
than those without T2DM [28–29]. The term type 3 diabetes is
proposed for AD [21,30]. Takeda et al. crossed APP23 transgenic
mice expressing Sw-APP mutant (mouse AD model) with leptin-
deficient ob/ob mice (mouse DM model) and observed that onset
of diabetes exacerbated AD-like cognitive dysfunction without
increase in brain Ab burden in the double transgenic mice (Sw-
APP ob/ob) mice. Remarkably, the Sw-APP ob/ob mice had
cerebrovascular inflammation and severe amyloid angiopathy.
The investigators concluded that diabetes accelerated memory
dysfunction via inflammation and Ab deposition in cerebrovascu-
lature [31].
Adiponectin is a serum adipokine secreted predominantly by
adipocytes and possesses insulin-sensitizing, anti-inflammatory and
anti-oxidant properties [32–33]. Serum adiponectin level is
decreased in obesity, obesity-related insulin resistance, T2DM
[34–35] and chronic inflammatory diseases such as coronary
artery disease [36]. Adiponectin is protective against many major
obesity-related pathologies including hypertension, atherosclerosis,
non-alcoholic fatty liver, non-alcoholic steatohepatitis, heart
failure, airway inflammation and some cancers [37]. Adiponectin
acts by binding to its receptors, adiponectin receptor type 1
(AdipoR1) and type 2 (AdipoR2). Most physiological actions of
adiponectin are mediated by activation of AMP-activated protein
kinase (AMPK) via phosphorylation at threonine172 (Thr172) to
yield phosphorylated AMPK (pAMPK). This adiponectin signal-
ing pathway requires an endosomal adaptor protein, APPL1
(adaptor protein with phosphotyrosine binding, pleckstrin homol-
ogy domains and leucine zipper motif) [38]. We hypothesize that
adiponectin is protective against Ab neurotoxicity in AD. In this
communication, we report that adiponectin is protective against
oxidative stress-induced cytotoxicity in human neuroblastoma cells
under Ab neurotoxicity and its underlying mechanisms of
neuroprotection.
Methods
The study was approved by the Hong Kong University-Hong
Kong West Cluster Institutional Review Board. Human neuro-
blastoma cells (SH-SY5Y cell line) were transfected with the wild-
type human APP (wt-APP) or Swedish-APP mutant (Sw-APP), and
control being SH-SY5Y cells transfected with empty-vector.
Cultured SH-SY5Y cells transfected with Sw-APP mutant over-
express APP with increased Ab production by 5–6 fold,
concomitant increase in secreted Ab42 and Ab40 and abnormal
intracellular Ab accumulation [39–41]. Cells transfected with wt-
APP overexpress APP with increased Ab production, but without
abnormal intracellular Ab accumulation [42]. The processing
pathways for secreted Ab and intracellular Ab are different
[41,43]. SH-SY5Y cells transfected with Sw-APP mutant were
used as an in-vitro system for further study. PC-12 (rat
pheochromocytoma) cells transfected with Sw-APP mutant were
shown to have increased Ab production and enhanced vulnera-
bility to oxidative stress-induced apoptosis [44].
Site-directed Mutagenesis of the Sw-APP
Site-directed mutagenesis was performed by polymerase chain
reaction (PCR) using the QuickChange Lightning Site-directed
Mutagenesis Kit (Stratagene) according to the manufacturer’s
protocol. The mutagenic primers used for generating the Sw-APP-
mutated construct were: forward GGAGATCTCTGAAGT-
GAACTTGGATGCAGAATTCCGAC, and reverse
GTCGGAATTCTGCATCCAAGTTCACTTCAGA-
GATCTCC. Non-mutated DNA was removed by DpnI endonu-
cleases digestion, and vector DNA containing the desired
mutations was transformed into XL10-Gold Ultracompetent cells
(Stratagene). The presence of the mutated sequence was confirmed
by sequencing both strands of the construct.
Cell Culture and Transfection
SH-SY5Y cell line was obtained from ATCC and maintained at
37uC (5% CO2/95% air) in DMEM containing 10% fetal bovine
serum (FBS) (Invitrogen, USA) and 1% penicillin and streptomy-
cin. SH-SY5Y cells were transfected with empty-vector, vector
carrying wt-APP and Sw-APP mutant under standard protocols
using Lipofectamine 2000 (Invitrogen, USA) according to
manufacturer’s instructions. Transfection was confirmed with
DNA sequencing and stably transfected cells were selected with
G418. Expression of the Sw-APP mutant with abnormal increase
of intracellular accumulation of Ab was confirmed with western
blot of cell lysates using rabbit antibody against amino acids 1–16
of the amino terminal of human Ab (Santa Cruz, CA).
Reverse Transcriptase Polymerase Chain Reaction for
Expression of Adiponectin Receptors
Reverse transcriptase-polymerase chain reaction (RT-PCR) was
performed to study the expression of adiponectin receptors,
AdipoR1 and AdipoR2, by SH-SY5Y cells. The primers used for
human AdipoR1 are: forward GAGCATCTTCCGCATTCATA
and reverse AAGAGCCAGGAGAAGCTGAG. The primers
used for human AdipoR2 are: forward GACTTCCTCTTG-
CATGGACA and reverse AAAGGAGATATTTGGGCGAA.
Enzyme Linked Immunosorbent Assay (ELISA) for Ab
Oligomers
Concentrations of secreted Ab oligomers in culture medium of
the three groups of cells were measured using ELISA recently
reported by our group [45] and compared using ANOVA. In
brief, the ELISA employed rabbit antibody against Ab N-terminal
(Ab residues1–14) (Abcam) as the capturing antibody and the Ab
oligomers antibody, 7A1a (New England Agent), as the detecting
antibody.
Measurement of Cytotoxicity under Oxidative Stress and
Neuroprotection by Adiponectin
Cell death and lysis (cytotoxicity) was assessed by examining
under light microscope and measured by assay of lactate
dehydrogenase (LDH) level. Cells were examined under light
microscope at 10X and 100X for cell morphology with loss of
dendritic spines (ballooning) as features suggestive of cell death.
LDH release into medium was quantitated by cytotoxicity
detection kit (Roche Applied Science, Germany) to assess
cytotoxicity of the three groups of SH-SY5Y cells: 1) cells
transfected with empty-vector, 2) cells transfected with wt-APP
and 3) cells transfected with Sw-APP mutant before and after
exposure to oxidative stress. Oxidative stress was induced with
addition of H2O2 to culture medium at 200 mM, 400 mM and
800 mM for 2 hours. Sw-APP transfected SH-SY5Y cells (26105)
Adiponectin Protective against Abeta Neurotoxicity
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e52354
were seeded on each well of a 24-well plate one day before use,
each well contained 500 ml of DMEM containing 10% FBS
(Invitrogen, USA) and 1% penicillin and streptomycin. Two hours
before addition of H2O2, fresh culture medium without FBS was
replaced and LDH level was measured 2 hours after addition of
H2O2 according to manufacturer’s instructions. Potential neuro-
protective effect of adiponectin was studied using Sw-APP
transfected SH-SY5Y cells by adding adiponectin to fresh culture
medium without FBS at 10 mg/ml for 2 hours before addition of
H2O2. Mouse recombinant adiponectin was produced and
purified as described previously [46]. LDH levels were used to
calculate percentage cytotoxicity which was expressed as fold of
cytotoxicity compared to percentage cytotoxicity of cells without
adiponectin treatment or exposure to H2O2. Folds of cytotoxicity
was compared between cells without adiponectin treatment or
exposure to H2O2 (fold = 1), cells without adiponectin treatment
before exposure to H2O2 and cells pretreated with adiponectin
before exposure to H2O2.
Immunoblotting
Culture medium was aspirated from wells of 24-well plate. Cells
were washed with ice-cold 16PBS and removed. 100 ml of 1x lysis
buffer (Cell Signaling Technology, USA) was added to each well
and incubated on ice for 20 minutes with gentle shaking to allow
complete lysis. The cell lysate was transferred to a 1.5 ml
centrifuge tube and centrifuged at 14,000 rpm at 4uC for 10
minutes. After centrifugation, the supernatant was transferred to
a new 1.5 ml centrifuge tube for Western blot analysis. Lysates of
cultured cells were assessed for Ab oligomers, by standard SDS-
PAGE electrophoresis and immunoblotting using an Ab oligomer
antibody, 7A1a, as described recently [45]. In addition, expression
levels of APPL1, total AMPK and pAMPK were studied by
standard SDS-PAGE and immunoblotting using anti-APPL1
antibody and anti-pAMPK antibody as primary antibodies.
Anti-human APPL1 antibody was synthezed by immunization of
New Zealand female rabbits with the recombinant full-length
APPL1 produced from Escherichia Coli using protocol described
previously [47]. Antibody against AMPKa subunit phosphorylated
at threonine172 (anti-pAMPK Thr172) was purchased from Cell
Signaling (Beverly, MA, USA). The specific signals were amplified
by addition of horseradish peroxidase-conjugated antibodies and
visualized using an enhanced chemiluminescence (Amersham,
UK).
Knockdown of AdipoR1, AdipoR2 and APPL1 Expression
by siRNA
Knockdown of AdipoR1 and AdipoR2 expression in Sw-APP
transfected SH-SY5Y cells was performed using RNA interference
by transfection with duplex stealth interference RNA (siRNA) for
adipoR1 and adipoR2 (Invitrogen, USA) or scrambled RNA
(negative control) using Lipofectamine 2000 according to manu-
facturer’s instructions as previously described by our group [47].
Knockdown of APPL1 expression in Sw-APP transfected SH-
SY5Y cells was achieved similarly by siRNA for APPL1
(Invitrogen, USA) or scrambled RNA (negative control). Successful
knockdown of AdipoR1, AdipoR2 and APPL1 expression was
confirmed by western blot of cell lysates. Cells were then
pretreated with adiponectin at 10 mg/ml for 2 hours before
addition of H2O2 (400 mM) followed by cytotoxicity assay 2 hours
later to study whether the neuroprotective effect of adiponectin
required expression of AdipoR1, AdipoR2 and APPL1.
Western Blot for NF-kB in Nuclear Fraction of SH-SY5Y
Cells
Levels of NF-kB activation of the three groups of cells, empty-
vector transfected, wt-APP transfected and Sw-APP transfected
SH-SY5Y cells were studied by western blot for NF-kB p65 in
nuclear fraction of the cells. Nuclear extracts of the SH-SY5Y cells
were prepared according to the standard procedures of a Nuclear
Extraction Kit (Panomics, Inc.; Beijing, China). Protein concen-
tration of the nuclear extracts was measured, followed by standard
procedures of protein transfer of western blot. The nitrocellulose
membrane was incubated with NF-kB p65 antibody (Santa Cruz,
California; dilution 1:1,000) or histone H3 antibody (Abcam, Inc.,
Figure 1. Human neuroblastoma cells (SH-SY5Ycells) express both adiponectin receptor 1 and 2. A. Reverse transcriptase polymerase
chain reaction (RT-PCR) for expression of adiponectin receptor 1 (AdipoR1) and 2 (AdipoR2) in human neuroblastoma cells (SH-SY5Ycells). RT-PCR
revealed the presence of PCR products of,200 base pair (bp) corresponding to the presence of messenger RNA for AdipoR 1 and 2. MCF7 cells serve
as the positive control cells which express both AdipoR 1 and AdipoR 2. B. Actin serve as the housekeeping gene and is expressed by both SH-SY5Y
and MCF-7 cells (PCR product of 78 bp). Experiments were performed twice with consistent results.
doi:10.1371/journal.pone.0052354.g001
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U.K.; dilution 1:1,000) as primary antibody at 4uC for overnight.
After washing with 1X TBST buffer 3 times (5 min each), the
membranes were incubated with anti-rabbit secondary antibody
(DAKO, Denmark; dilution 1:5,000) at RT for one hour and then
washed again with 1X TBST buffer 3 times. The membranes were
then immersed in ECL detection solution (Amersham Biosciences)
for 1 min in darkness. Excess detection solution was drained off
and the membrane was then wrapped in transparent wrapping
film and exposed to X-ray film for 2 min. Images of the X-ray film
were analyzed with Image-J. The effect of adiponectin on NF-kB
activation of Sw-APP transfected SH-SY5Y cells was further
studied. Sw-APP transfected SH-SY5Y cells were cultured in 6-
well plate at one million cells per well one night before the
experiment. Sw-APP transfected SH-SY5Y cells were divided into
4 groups: control cells without pretreatment with adiponectin
(ADN) or exposure to H2O2 (group 1), cells treated with ADN
(10 mg/ml) for 2 hours without exposure to H2O2 (group 2), cells
exposed to 400 mM H2O2 for 2 hours without ADN pretreatment
before exposure to H2O2 (group 3), and cells pretreated with ADN
for 2 hours before exposure to 400 mM H2O2 for 2 hours (group
4). After treatment, nuclear extracts of the cells were prepared and
western blot for NF-kB p65 was performed as described above.
The amount of NF-kB p65 was quantitated by Image-J analysis.
Statistical Analysis
Western blot results of different groups of cells were quantified
by Image-J and compared by one-way ANOVA using Newman-
Keuls multiple comparison test with p-value ,0.05 considered as
statistically significant. All ELISA and cytotoxicity experiments
were performed at least 3 times and the mean values of results
from different groups of cells were similarly compared by one-way
ANOVA using Newman-Keuls multiple comparison test with p-
value ,0.05 considered as statistically significant.
Results
Human Neuroblastoma Cells Express both Adiponectin
Receptor 1 and 2
RT-PCR results demonstrated that SH-SY5Y cells express both
AdipoR1 and AdipoR2 (Figure 1). A previous study has
demonstrated that SH-SY5Y cells express AdipoR2 by western
blot analysis [48].
Figure 2. Sw-APP transfected SH-SY5Y cells secrete Ab
oligomers and had increased intracellular Ab oligomers level.
A. Western blot analysis of cell lysates with Ab antibody. Immunoblot-
ting demonstrated that SH-SY5Y cells transfected with Swedish amyloid
precursor protein (Sw-APP) mutant had increased amount of in-
tracellular Ab oligomers (tetramers and hexamers) compared to SH-
SY5Y cells transfected with wild-type amyloid precursor protein (APP),
empty-vector (vector) or untransfected SH-SY5Y cells (UT). B. Image J
quantitiative analysis confirmed that Sw-APP transfected cells (Sw-APP)
had increased amount of intracellular hexamers compared to empty-
vector transfected (vector) (p,0.05) or untransfected (UT) cells
(p,0.05). C. ELISA for concentration of secreted Ab oligomers in
cultured medium. Sw-APP transfected SH-SY5Y cells (Sw-APP) secreted
greater amount of extracellular Ab oligomers than wt-APP transfected
cells (APP) (p = 0.0001), which also secreted greater amount of
extracellular Ab oligomers than empty-vector transfected cells (vector)
(p,0.05). Results shown were mean values from 3 independent
cultures, and compared by one-way ANOVA using Newman-Keuls
multiple comparison test.
doi:10.1371/journal.pone.0052354.g002
Figure 3. Western blot analysis of cell lysates for phosphory-
lated AMP-activated protein kinase (pAMPK) and the endoso-
mal adaptor protein APPL-1 (adaptor protein with phospho-
tyrosine binding, pleckstrin homology domains and leucine
zipper motif). Immunoblotting demonstrated that SH-SY5Y cells
transfected with Sw-APP mutant (Sw-APP) had increased pAMPK than
SH-SY5Y cells transfected with wt-APP (APP) which had increased
pAMPK than control cells transfected with empty-vector (vector).
Expression of APPL1 was indifferent among the three groups of cells.
Experiments were repeated 3 times with consistent results.
doi:10.1371/journal.pone.0052354.g003
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Human Neuroblastoma Cells Stably Transfected with Sw-
APP Mutant and wt-APP had Increased AMPK Activation
As expected, Western blot analysis of cell lysates revealed that
Sw-APP transfected SH-SY5Y cells had higher level of in-
tracellular Ab oligomers than empty-vector and wt-APP trans-
fected SH-SY5Y cells (p,0.05) (Figure 2A and 2B). ELISA
revealed that Sw-APP transfected cells had higher concentration of
secreted Ab oligomers in medium than empty-vector and wt-APP
transfected cells (Figure 2C). Western blot analysis also revealed
that Sw-APP transfected cells had higher level of pAMPK than wt-
APP transfected cells (p = 0.0002), which had higher level of
pAMPK than empty-vector transfected control cells (p = 0.0002)
whereas APPL1 expression was indifferent between the 3 groups of
cells (Figure 3). This may suggest that pAMPK is important for
survival of SH-SY5Y cells in the presence of Ab neurotoxicity,
hence Sw-APP and wt-APP transfected cells increased AMPK
activation as a compensatory response for survival, especially with
abnormal intracellular Ab accumulation in Sw-APP transfected
cells.
Human Neuroblastoma Cells Transfected with Sw-APP
Mutant were more Vulnerable to Cytotoxicity Under
Oxidative Stress
Without addition of H2O2, the basal cytotoxicity/death rates of
Sw-APP transfected, wt-APP transfected and empty-vector
transfected SH-SY5Ycells were 0.807%, 0.863% and 0.848%
respectively, being indifferent (Figure 4A). Upon exposure to
H2O2 induced oxidative stress, Sw-APP transfected SH-SY5Ycells
had higher cytotoxicity compared to wt-APP transfected cells
(p,0.0001) which had higher cytotoxicity compared to empty-
vector transfected cells (p,0.0001) (Figure 4B). This supports that
increased Ab production particularly with abnormal intracellular
Ab accumulation enhances vulnerability to cytotoxicity with cell
lysis under oxidative stress [45].
Adiponectin was Protective against Ab Induced Neuronal
Cytotoxicity Under Oxidative Stress
Importantly, pretreatment of Sw-APP transfected SH-SY5Y
cells with adiponectin at 10 mg/ml for 2 hours before exposure to
H2O2 led to significant reduction of cytotoxicity under oxidative
stress induced by H2O2 at concentration of 200 mM to 800 mM
(Figure 5). Adiponectin of 10 mg/ml is at physiological concen-
tration as documented previously [79]. The most marked pro-
tective effect was noted at 400 mM H2O2 as adiponectin
pretreatment lowered cytotoxicity from 12.4 folds to 2.7 folds
(p,0.0001). This strongly supports that adiponectin at physiolog-
ical concentration of 10 mg/ml protects SH-SY5Y cells with Ab
neurotoxicity against cytotoxicity under oxidative stress. To ensure
that adiponectin protection against cytotoxicity under oxidative
stress induced by H2O2 in Sw-APP transfected SH-SY5Y cells was
due to the effect of adiponectin binding to its cell surface receptors
AdipoR1 and AdipoR2, we performed experiments using Sw-APP
transfected SH-SY5Y cells with knockdown of AdipoR1 and
AdipoR2 expression by RNA interference. The results showed
that the protective effect of adiponectin against cytotoxicity under
oxidative stress was lost in Sw-APP transfected SH-SY5Y cells with
knockdown of AdipoR1 or AdipoR2, but preserved in control Sw-
APP transfected SH-SY5Y cells without knockdown of either
receptor (scramble RNA) (Figure 5B). This confirms that pro-
tective effect of adiponectin against Ab induced neuronal
cytotoxicity under oxidative stress requires binding of adiponectin
to its cell surface receptors. With this, the possibility that
adiponectin may directly interact with Ab oligomers leading to
blockade of Ab oligomers-associated cytotoxic effects is unlikely.
Adiponectin Protection against Ab Induced Neuronal
Cytotoxicity Under Oxidative Stress Involved APPL1-
dependent AMPK Activation
We further investigated the mechanisms of neuroprotection by
adiponectin against Ab neurotoxicity. As important cellular
functions of adiponectin are exerted via APPL1-mediated AMPK
activation leading to increased intracellular pAMPK, we pro-
ceeded to study whether protective effect of adiponectin against
Ab neurotoxicity involved APPL1-dependent AMPK activation.
Using Sw-APP transfected SH-SY5Y cells with knockdown of
APPL1 expression by RNA interference (Figures 6A and 6B), we
found that the neuroprotective effect of adiponectin against
cytotoxicity under H2O2 induced oxidative stress was lost in cells
with knockdown of APP1 expression but preserved in cells without
knockdown of APPL1 expression (Figure 6C). These suggest that
Figure 4. Cytotoxicity of SH-SY5Ycells transfected with empty
vector, wild-type APP and the Swedish-APP mutant. A. LDH
assay revealed that the basal cytotoxicity of Sw-APP transfected (sw-
APP), wt-APP transfected (APP) and empty-vector transfected (vector)
SH-SY5Ycells are indifferent. B. Sw-APP transfected (Sw-APP) cells had
increased cytotoxicity under oxidative stress induced by hydrogen
peroxide (500 mM) than wt-APP transfected (APP) (p,0.0001) which
had increased cytotoxicity under oxidative stress than empty-vector
transfected (vector) cells (p,0.0001). Results shown were mean values
from 3 independent cultures, and compared by one-way ANOVA using
Newman-Keuls multiple comparison test.
doi:10.1371/journal.pone.0052354.g004
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Figure 5. Adiponectin protection against cytotoxicity of SH-SY5Y cells transfected with Swedish-APP (Sw-APP) mutant under
oxidative stress. (A) Percentage cytotoxicity of SH-SY5Y cells transfected with Sw-APP mutant under oxidase stress by different concentrations of
hydrogen peroxide (H2O2) without and with pretreatment of adiponectin at 10 mg/ml expressed as fold of cytotoxicity relative to cytotoxicity without
exposure to H2O2 (untreated, fold = 1) were shown on y-axis. In all three H2O2 concentrations, percentage cytotoxicity were significantly reduced with
adiponectin pretreatment (p,0.05 for 200 mM H2O2, p,0.0001 for 400 mM H2O2 and p,0.05 for 800 mM H2O2). (2) ADN=without adiponectin
pretreatment, (+) ADN=with adiponectin pretreatment. Results shown were mean values from 5 independent cultures, and compared by one-way
ANOVA using Newman-Keuls multiple comparison test. (B) Using Sw-APP transfected SH-SY5Y cells with knockdown of AdipoR1 or AdipoR2
expression for the cytotoxicity experiments, it was observed that the protective effect of adiponectin against cytotoxicity under oxidative stress was
preserved in control Sw-APP transfected SH-SY5Y cells without knockdown of AdipoR1 or AdipoR2 (scramble RNA+ADN+400 mM H2O2), but lost in
cells with knockdown of AdipoR1 (AdipoR1 siRNA+ADN+400 mM H2O2) or AdipoR2 (AdipoR2 siRNA+ADN+400 mM H2O2) expression. This confirms
that protective effect of adiponectin against cytotoxicity under oxidative stress in Sw-APP transfected SH-SY5Y cells required binding of adiponectin
to its cell surface receptors AdipoR1 or AdipoR2. untreated = Sw-APP transfected SH-SY5Y cells without exposure to H2O2, 400 mM H2O2 = Sw-APP
transfected SH-SY5Y cells exposed to 400 mM H2O2, ADN+400 mM H2O2 = Sw-APP transfected SH-SY5Y cells pretreated with adiponectin before
exposure to 400 mM H2O2. Results shown were mean values from 3 independent cultures, and compared by one-way ANOVA using Newman-Keuls
multiple comparison test.
doi:10.1371/journal.pone.0052354.g005
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neuroprotective effect of adiponectin against Ab mediated
neuronal cytotoxicity under oxidative stress is dependent on
APPL1. In addition, Western blot analysis of cell lysates revealed
that Sw-APP transfected SH-SY5Y cells pretreated with adipo-
nectin before exposure to H2O2 had higher pAMPK level than
Sw-APP transfected SH-SY5Y cells without adiponectin pre-
Figure 6. Adiponectin neuroprotection against cytotoxicity under oxidative stress is mediated via APPL1-dependent AMPK
activation. A. Western blot analysis of control Swedish-APP mutant transfected SH-SY5Y cells (Sw-APP) and similar cells transfected with scramble
RNA (Sw-APP+scramble RNA) revealed APPL1 expression. Successful knowkdown of APPL1 expression by RNA interference was shown on
immunoblotting of cell lysate of Sw-APP transfected SH-SY5Y cells transfected with short interference RNA for APPL1 (Sw-APP+siRNA). B. Image-J
analysis confirmed successful knockdown of APPL1 expression in Sw-APP transfected SH-SY5Y cells by siRNA compared to control cells transfected
with scramble RNA (p,0.0001). Transfection experiments were performed 3 times with consistent results. C. Neuroprotective effect of adiponectin
against cytotoxicity under oxidative stress (400 mM H2O2) was lost in Sw-APP transfected SH-SY5Y cells with knockdown of APPL1 expression
(siRNA+ADN+400 mM H2O2), but preserved in cells without knockdown of APPL1 expression (scramble siRNA+AND+400 mM H2O2, p,0.0001). This
suggests that adiponectin neuroprotection against Ab-induced cytotoxicity under oxidative stress requires APPL1. Fold of percentage cytotoxicity
relative to cells not exposed to H2O2 (untreated, fold = 1) was shown on y-axis. untreated= Sw-APP transfected SH-SY5Y cells without exposure to
H2O2, 400 mM H2O2 = Sw-APP transfected SH-SY5Y cells exposed to 400 mM H2O2, ADN+400 mM H2O2 = Sw-APP transfected SH-SY5Y cells pretreated
with adiponectin before exposure to 400 mM H2O2. Results shown were mean values from 3 independent cultures, and compared by one-way
ANOVA using Newman-Keuls multiple comparison test. D. Adiponectin induced AMPK activation. Western blot analysis of cell lysates from Sw-APP
transfected SH-SY5Y cells exposed to oxidative stress (400 mM H2O2) demonstrated that cells pretreated with adiponectin (ADN) had increased
phosphorylated AMPK (pAMPK) compared to cells without adiponectin pretreatment whereas APPL1 and total AMPK levels were similar. This strongly
suggests that adiponectin neuroprotection against cytotoxicity under oxidase stress in Sw-APP transfected SH-SY5Y cells is mediated via APPL1-
dependent AMPK activation. Western blot analysis were performed for 3 independent cultures with consistent results.
doi:10.1371/journal.pone.0052354.g006
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treatment, while total AMPK level was similar (Figure 6D). These
together suggest that the protective effect of adiponectin against
Ab induced neuronal cytotoxicity under oxidative stress is
mediated via APPL1-dependent AMPK activation.
Human Neuroblastoma Cells Transfected with Sw-APP
Mutant and wt-APP had Increased NF-kB Activation
Western blot analysis of nuclear extract for p65 component of
NF-kB (NF-kB p65) revealed that Sw-APP transfected SH-SY5Y
cells had higher NF-kB p65 level than wt-APP transfected cells
(p,0.0001), which had higher NF-kB p65 level than empty-vector
transfected cells (p,0.001) (Figure 7). These suggest that Ab over-
production and Ab neurotoxicity lead to increased NF-kB
activation, consistent with the concept that neuroinflammation is
one of the pathogenetic mechanisms in AD.
Figure 7. Western blot for nuclear factor-kappa B (NF-kB)
activation. A. SH-SY5Ycells transfected with the Swedish-APP mutant
(Sw-APP) had significantly higher level of nuclear NF-kB p65 than cells
transfected with wild-type APP (APP), which had higher level of nuclear
NF-kB p65 than cells transfected with empty-vector (vector). The
control nuclear protein was histone 3. B Image J and statistical analysis
confirmed statistically significant difference in the level of NF-kB
activation. Sw-APP transfected SH-SY5Ycells under greatest Ab neuro-
toxicity had the highest level of nuclear NF-kB p65 more than that of
wt-APP transfected cells (p,0.0001), which had higher level of NF-kB
p65 than empty-vector transfected cells without Ab neurotoxicity
(p,0.001). Results shown were mean values from 3 independent
cultures, and compared by one-way ANOVA using Newman-Keuls
multiple comparison test.
doi:10.1371/journal.pone.0052354.g007
Figure 8. Adiponectin (ADN) suppressed NF-kB activation. A.
Western blot of nuclear extracts revealed that SH-SY5Y cells transfected
with Swedish-APP mutant had high level of NF-kB p65 signifying NF-kB
activation (lane 1), and treatment with adiponectin (ADN) at 10 mg/ml
for 2 hours resulted in reduced NF-kB activation (lane 2). Sw-APP
transfected cells exposed to 400 mM H2O2 for 2 hours had high level of
NF-kB activation (lane 3), and importantly Sw-APP transfected cells
pretreated with adiponectin at 10 mg/ml for 2 hours before exposure to
400 mM H2O2 had reduced NF-kB activation (lane 4). Control nuclear
protein was histone H3. B. Statistical analysis of imaging J values
revealed that Sw-APP transfected SH-SY5Y cells (Sw-APP) had significant
reduction level of NF-kB activation after treatment with ADN (Sw-
APP+ADN, p,0.0005). Consistently, Sw-APP transfected SH-SY5Y cells
exposed to oxidative stress of 400 mM H2O2 (Sw-APP+400 mM H2O2)
had significantly reduced level of NF-kB activation with adiponectin
pretreatment at 10 mg/ml for 2 hours before exposure to oxidative
stress of 400 mM H2O2 (Sw-APP+AND+400 mM H2O2, p,0.0005). This
raises the possibility that one mechanism underlying adiponectin
neuroprotection against Ab neurotoxicity-induced cytotoxicity under
oxidative stress is suppression of NF-kB activation. Results shown were
mean values from 3 independent cultures, and compared by one-way
ANOVA using Newman-Keuls multiple comparison test.
doi:10.1371/journal.pone.0052354.g008
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NF-kB Activation was Reduced in Sw-APP Transfected
Human Neuroblastoma Cells Pretreated with
Adiponectin
We further studied whether adiponectin might suppress NF-kB
activation especially adiponectin is known to possess anti-in-
flammatory action. Western blot analysis of nuclear fraction of Sw-
APP transfected SH-SY5Y cells revealed that cells treated with
adiponectin at 10 ug/ml for 2 hours had significantly reduced NF-
kB activation compared to untreated cells (p,0.0001) (Figure 8A
and 8B). Similar reduction of NF-kB activation in Sw-APP
transfected SH-SY5Y cells exposed to H2O2 induced oxidative
stress cells was observed with adiponectin pretreatment before
exposure to H2O2 (p,0.0001) (Figure 8A and 8B). These raise the
possibility that one of the mechanisms underlying adiponectin
protection against Ab neurotoxicity was suppression of NF-kB
activation, hence attenuating neuroinflammation.
Discussion
Ab inhibits enzymes of mitochondrial oxidative phosphorylation
and key enzymes of Krebs cycle, leading to mitochondrial
dysfunction, reduced ATP production (energy failure), and
generation of ROS and reactive nitrogen species (RNS) such as
superoxides and nitrites. ROS and RNS contribute to oxidative
stress which causes oxidation and nitration of proteins, nucleic
acids and lipids leading to mitochondrial dysfunction, altered Ca2+
homeostasis, membrane damage and altered proteasome function
with abnormal protein accumulation [49]. ROS also activate
genes involved in inflammatory pathways such as IL-6, interferon-
gamma (IFN-c) and inducible nitric oxide synthase (iNOS) [17].
Activation of iNOS leads to excess endogenous nitric oxide (NO)
which causes S-nitrosylation of dynamin-related protein-1, result-
ing in mitochondrial fission, synaptic loss and neuronal damage
[50]. Hence, oxidative stress causes cellular dysfunctions, neuronal
degeneration and death [49,51]. Importantly, increased oxidative
stress occurs early in AD [51–53].
We demonstrated that Sw-APP transfected human neuroblas-
toma cells over-producing Ab had increased susceptibility to
cytotoxicity under oxidative stress. This supports that Ab
neurotoxicity mediated oxidative stress and mitochondrial dys-
function play important roles in AD pathogenesis [26,49,51]. The
Sw-APP transfected SH-SY5Y cells had higher secreted Ab
oligomers level in culture medium and intracellular Ab oligomers
level compared to empty-vector transfected cells. We are uncertain
whether the increased susceptibility to cytotoxicity under oxidative
stress is due to the extracellular or intracellular Ab oligomers, but
probably the latter. Our observation that AMPK activation was
increased in Sw-APP transfected cells compared to wt-APP and
empty-vector transfected cells may imply that increased pAMPK
level from AMPK activation is beneficial for neuronal survival
under Ab neurotoxicity. AMPK is a sensor of cellular energy level
and is activated by increase in AMP to ATP ratio, hence functions
to preserve cellular energy. AMPK activation upregulates ATP-
producing catabolic pathways such as uptake and metabolism of
glucose and fatty acids, and downregulates ATP-consuming
anabolic pathways such as synthesis of glycogen, cholesterol and
proteins [54]. It is likely that Ab neurotoxicity in the Sw-APP
transfected neuroblastoma cells induces mitochondrial dysfunction
leading to decreased ATP level, hence stimulates AMPK
activation. Treatment of cultured embryonic rat hippocampal
neurons under glucose deprivation with a potent AMPK activator
led to improved cell survival. Similar beneficial effect was also
found in neurons exposed to Ab peptide, sodium cyanide
(mitochondrial toxin) and glutamate [55]. However, Thornton et
al. reported that treatment of primary mouse cortical neurons with
Ab42 induces AMPK activation which leads to increased tau
phosphorylation. This pathway of Ab42 induced AMPK activa-
tion involves the N-methyl-D-aspartate (NMDA) receptor as
AMPK activation is inhibited by memantine, a partial NMDA
receptor antagonist used in treatment of AD [56]. Consistently,
Vingtdeux et al. reported that activated AMPK (pAMPK) is
abnormally accumulated in cerebral neurons of patients with
tauopathies including AD. In AD, pAMPK is accumulated in
neuropil threads and dystrophic neurites surrounding amyloid
plaques in .90% of neurons bearing neurofibrillary tangles and
pre-tangles. The investigators proposed that AMPK might
regulate neurodegeneration by controlling tau phosphorylation
[57]. Whether AMPK activation leads to tau phosphorylation
cannot be addressed in our study.
Une at al. reported that plasma adiponectin level was
significantly higher in mild cognitive impairment (MCI) and AD
patients than normal controls (NC), whereas CSF adiponectin
level was significantly higher in MCI than NC [58]. This increased
adiponectin level may be a compensatory response to protect
against neurodegeneration in MCI or early AD. However, van
Himbergen et al. studied 840 dementia-free Framingham Heart
Study participants over a mean follow-up period of 13 years and
reported that 159 persons developed dementia (125 AD); and after
adjustment of other risk factors, only adiponectin in women was
associated with an increased risk of all-cause dementia (hazard
ratio [HR] 1.29, p= 0.054) and AD (HR 1.44, p= 0.050) per 1
standard deviation increase in adiponectin level. In addition,
women with baseline adiponectin levels above the median had
a higher risk of all-cause dementia (HR 1.63, p= 0.04) and AD
(HR 1.87, p = 0.01) compared to those with adiponectin levels
below median [59]. The exact role of adiponectin in human
cognitive functions awaits further clarification. Importantly, our
results demonstrated that adiponectin at a physiological concen-
tration of 10 mg/ml (physiological serum concentration 3–30 mg/
ml) is protective against cytotoxicity of SH-SY5Y cells expressing
Sw-APP mutant under H2O2 induced oxidative stress; and this
protective effect of adiponectin against Ab neurotoxicity is
dependent on APPL1, likely mediated via APPL1-dependent
AMPK activation. APPL1 plays important role as an endosomal
adaptor protein in various cellular signaling pathways [38,60].
AMPK activation promotes ATP producing catabolic pathways
including glucose uptake and metabolism which is diminished in
AD brain with insulin deficiency and resistance [21]. AMPK
activation protects and confers survival benefits to neurons against
oxidative, metabolic and excitotoxic stress [54–55]. Resveratrol,
a neuroprotective plant polyphenol, promotes neurite outgrowth
and mitochondrial biogenesis in neurons via AMPK activation
[61]. In addition, adiponectin-mediated activation of AMPK,
p38MAPK and Rab5 leads to increased glucose transporter 4
(Glut4) membrane translocation [62] which also promotes
neuronal glucose uptake and metabolism. Insulin is important
for neuronal function and survival, and reduced cerebral insulin
and insulin-like growth factor (IGF-1) levels, as well as impaired
neuronal insulin signaling are noted in AD brain [63–64]. Both the
expression and function of insulin and IGF-1 deteriorate with
progression of AD [57], and intranasal insulin improves cognition
and modulates Ab in early AD [65]. The insulin-sensitizing action
of adiponectin [33,60] may be another mechanism of neuropro-
tection in AD which cannot be addressed in our study.
Neuroinflammation is increasingly recognized as an important
element in AD [22,24,66–67]. Reactive astrocytes in close
proximity to Ab plaques and activated microglia secrete in-
flammatory mediators including IL-1b, TNF-a, IL-6, interleukin-
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18 (IL-18) and iNOS which generate free radicals such as NO. In
addition, Ab undergoes non-enzymatic glycation to form ad-
vanced glycation endproducts (AGEs) which bind to receptor for
AGES (RAGE). This AGES/RAGE signaling activity upregulates
activity of the transcription factor, nuclear factor kappa-B (NF-kB)
[68–70]. NF-kB activation is a central event of neuroinflammation
in AD [71], and is predominantly found in neurons and glial cells
at regions surrounding Ab plaques in AD brain [72–75]. NF-kB
activation triggers expression of pro-inflammatory molecules
including cytokines and chemokines which contribute to neuronal
cytotoxicity in AD [71]. This is consistent with our observation
that Sw-APP transfected and wt-APP transfected neuroblastoma
cells overproducing Ab have increased NF-kB activation than
empty-vector transfected cells not overproducing Ab. Importantly,
NF-kB activation in Sw-APP transfected neuroblastoma cells
diminished with adiponectin treatment in parallel with its
protective effect against cytotoxicity under oxidative stress. This
raises the possibility that suppression of NF-kB activation is one
mechanism underlying neuroprotective effect of adiponectin
against Ab-induced neuronal cytotoxicity under oxidative stress.
Adiponection was recently reported to block IL-18 mediated
endothelial cell death [76]. Treatment of endothelial cells with IL-
18 suppressed Akt (protein kinase B) phosphorylation and its
associated kinase activity [77], and induced IkB kinase (IKK)-NF-
kB-dependent phosphatase and tensin homolog (PTEN) activa-
tion, hence promoted endothelial cell death [76]. Pretreatment
with adiponectin stimulated APPL1-dependent AMPK activation,
reversed Akt inhibition, inhibited IKK-NF-kB dependent PTEN
expression in an AMPK-dependent manner, hence blocked IL-18
mediated endothelial cell death [76]. This is consistent with the
cytoprotective effect of adiponection via AMPK activation which
inhibits IKK-NF-kB dependent-PTEN pathway [60]. IL-18 is
upregulated in AD brain [78] and IL-18 production by peripheral
blood cells is increased in AD patients, the level of which correlates
with cognitive impairment [79]. These suggest that IL-18 related
inflammatory pathways are exacerbated in AD, which can be
attenuated by adiponectin. In addition, adiponectin was reported
to protect neurons against ischemic-reperfusion injury in a rat
model of stroke through anti-inflammatory action via inhibition of
NF-kB activation [80].
This is the first report that adiponectin is protective in human
neuroblastoma cells with Ab neurotoxicity. Adiponectin has been
reported to be neuroprotective in 1) SH-SY5Y cells against MPP+-
induced cytotoxicity [81], 2) SH-SY5Y cells against acetaldehyde-
induced apoptosis [48], 3) a mouse model of epilepsy against kainic
acid-induced excitotoxicity [82] and 4) a rat model of stroke
against cerebral ischemia-reperfusion injury [80]. It is encouraging
that a recent study reported that intense expression of AdipoR1
was noted in the hypothalamus and the nucleus basalis of Meynert
in basal forebrain which is frequently affected in AD [83]. Further
studies are needed to confirm the neuroprotective effect of
adiponectin in Ab neurotoxicity, which bears potential for novel
therapies against AD. Interestingly, another adipokine, leptin has
been shown to reduce Ab levels in neuronal cells via AMPK
activation [84], and reduce pathology and improve memory in
a transgenic mouse AD model [85].
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